Drugs / AZD1390
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05182905 | May 2022 → Jun 2026 overdue | glioblastoma | Nader Sanai | Active not recruiting | No outcome recorded |
| Phase 17 trials | ||||||
| Phase 1 | NCT07643870 | Jun 2026 → Apr 2028 expected | high grade malignant neoplasm | AstraZeneca | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06894979 | Jun 2025 → Mar 2028 expected | childhood astrocytic tumor, diffuse intrinsic pontine glioma, glioblastoma | Children's Oncology Group | Recruiting | No outcome recorded |
| Phase 1 | NCT05678010 | May 2023 → May 2028 expected | carcinoma, metastatic malignant neoplasm | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05116254 | Jul 2022 → Dec 2025 | soft tissue sarcoma | The Netherlands Cancer Institute | Terminated | No outcome recorded |
| Phase 1 | NCT04550104 | Mar 2021 → Mar 2026 overdue | non-small cell lung carcinoma | University of Leeds | Recruiting | No outcome recorded |
| Phase 1 | NCT03423628 | Apr 2018 → Sep 2026 overdue | brain cancer, glioblastoma, malignant tumor of meninges | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03215381 | Oct 2017 → Feb 2018 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT03970447 | Jul 2019 → Jun 2028 expected | glioblastoma | Global Coalition for Adaptive Research | Recruiting | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD1390 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05116254 ↗ |
| Action | Inhibit | “In this study the DDR candidate inhibitor is new drug candidate AZD1390 targeting ATM (Ataxia Telangiectasia Mutated).” NCT05116254 ↗ |
| Modality | Small molecule | — CHEMBL4594429 ↗ |
| Route | Oral | “Oral tablet” NCT04550104 ↗ |
| Target | ATM | “In this study the DDR candidate inhibitor is new drug candidate AZD1390 targeting ATM (Ataxia Telangiectasia Mutated).” NCT05116254 ↗ |